0      0

JL1116EH - JL1116EH: Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)

‐ Nov 2, 2023 2:00pm

Full author listing

Kerry A. Rogers (1), Xiaoxiao Lu (2), Bruno Emond (3), Zhijie Ding (2), Patrick Lefebvre (3), Marie-Hélène Lafeuille (3), Heena Mavani (2), Zaina P. Qureshi (2), Nilanjan Ghosh (4)

1) Division of Hematology, The Ohio State University, Columbus, 2)Janssen Scientific Affairs, LLC, Horsham, PA, USA, 3) Analysis Group, Inc., Montréal, QC, Canada, 4)Levine Cancer Institute, Atrium Health, Charlotte, NC


You must be logged in and own this session in order to post comments.